Sanford Health has provided $23m in funding to increase the regenerative cell therapy provider's series D round to $43m, having initially supplied the first $20m in 2017.
US-based regenerative medicine and cell therapy technology developer InGeneron extended its series D round to $43m on Tuesday with a $23m investment from hospital operator Sanford Health.
The corporate had provided the initial $20m in March 2017 as part of a cooperation agreement and has structured the capital in various tranches based on the company’s development.
Founded in 2006, InGeneron is developing technology that helps doctors treat musculoskeletal conditions by administering regenerative cells taken from a patient’s own fat tissue.
…
